Zhejiang Starry Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Zhejiang Sitaili Pharmaceutical Co., Ltd. was established in 1997. It is a high-tech enterprise specializing in the research and development, production, and sales of X-CT non ionic contrast agent series and quinolone series raw materials and intermediates. It is the largest and most comprehensive factory in China for contrast agent generic drugs. During the 12th Five Year Plan period, the company extended to the front and end of the industrial chain. In January 2011, it established an intermediate production base in Zhangshu, Jiangxi - Jiangxi Sitali Pharmaceutical Co., Ltd. In June 2012, it established a preparation factory in Jinshan, Shanghai - Shanghai Sitali Pharmaceutical Co., Ltd. On March 9, 2016, the company was listed on the Shanghai Stock Exchange with stock code 603520. In November 2018, the company successfully acquired a domestic peer enterprise - Zhejiang Taizhou Haishen Pharmaceutical Co., Ltd., entering a fast lane of rapid development. In the past twenty years, the company has maintained a good and stable development momentum, becoming a leading enterprise in the domestic production of non ionic contrast agent raw materials for X-CT. Among them, the production capacity and output of iodohexanol raw materials rank first in China. The company's product quality is stable and has obtained certifications from multiple developed countries. The raw materials produced by the company, including Iohexol, Iodopanol, Ioxaxol, Levofloxacin, and Levofloxacin Hydrochloride, have obtained the national drug GMP certificate; The raw materials of Iohexol and Iodopanol have obtained the EU CEP certificate; The raw materials of Iohexol, Iodopanol, Ioxaxol, Levofloxacin, and Levofloxacin Hydrochloride have obtained domestic registration approvals; The raw materials of Iohexol, Iodopanol, Ioxaxol, and Levofloxacin have obtained registration approvals from India; The raw materials of Iohexol, Iodopanol, Levofloxacin, Losoprofen Sodium, and the intermediate Levofloxacin Cyclic Ester have obtained the Japanese registration certificate. At present, there are four global manufacturers of iohexol raw material drugs that have obtained the EU CEP certificate, and only Stellite (including Haishen Pharmaceutical) is the only one in China; There are four global manufacturers of iohexol raw materials that have obtained a Japanese registration certificate, and Stellite (including Haishen Pharmaceutical) is also one of them. In terms of quinolone series raw materials, the company is at a leading level in the field of impurity separation and synthesis of levofloxacin series products in China, and is one of the largest production enterprises of levofloxacin series in China. The company has long focused on the sustainable development strategy of X-ray contrast agents, attaches great importance to independent research and development capabilities, and has achieved fruitful results. The company is the Zhejiang Provincial Enterprise Technology Center and the Zhejiang Provincial High tech Research and Development Center for Non ionic Contrast Agents. The project of "Iohexol as a raw material for non ionic X-CT contrast agents" and the project of "Industrialization of Pazufloxacin, a key intermediate of the fourth generation quinolone antibacterial drugs" undertaken by the company have both obtained the "National Torch Plan Project Certificate" issued by the Torch High tech Industry Development Center of the Ministry of Science and Technology of the People's Republic of China. The raw materials Iohexol and Pazufloxacin have also been rated as "high-tech products of Zhejiang Province" by the Zhejiang Provincial Department of Science and Technology. The project "Development and Industrialization of the Synthesis Process of High Purity Non ionic X-CT Contrast Agent Iohexol" has been awarded the "Second Prize in Zhejiang Province Science and Technology" and the "First Prize in Taizhou City Science and Technology Progress" by the Zhejiang Provincial People's Government and the Taizhou City People's Government, respectively. In addition, the company has won over 400 awards of various sizes since its establishment. The company has established a 45 million yuan charity naming fund and has donated over 20 million yuan to various sectors of society. In 2020, Shanghai Starry Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, applied for the first national new Class 4 registration (deemed to have passed the "drug consistency evaluation") for products such as Iodopanol Injection, Iohexol Injection, and Ioxaxol Injection, and obtained registration approval from the National Drug Administration. Shanghai Starry Pharmaceutical Co., Ltd. has filled the gap in the pharmaceutical industry chain of Starry Pharmaceutical in the pharmaceutical sector, enabling the company to successfully complete the industrial transformation and upgrading from raw materials to pharmaceutical products. In 2021, Shanghai Stryker Iohexol and Iohexol Injection won the bid for the fifth batch of national centralized procurement, achieving the landing and deepening of the company's integrated strategic layout of the entire industry chain of "intermediates raw materials preparations" for iodine contrast agents. The company adheres to the business philosophy of "aggregating life energy and caring for human health" and the development policy of "replacing imports with specialized ones and filling domestic gaps", continuously enriching the X-ray contrast agent series products. The company will strive to become a well-known pharmaceutical enterprise in China and even globally, creating an outstanding "Sitali" pharmaceutical brand and contributing to the health cause of all humanity. |
| Headquarter | Taizhou |
| Establish Date | 9/15/1997 |
| Listed Code | 603520.SH |
| Listed Date | 3/9/2016 |
| Chairman | Hu Jian. |
| CEO | Shen Weiyi. |
| Website | www.starrypharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
